1-3 of 3
Roxanne Ferdinand
Close
Sort by
Journal Articles

Efficacy and Safety Following Dose Reduction of Bosutinib or Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: Analysis of the Phase 3 BFORE Trial

Tim H. Brummendorf, MD, Carlo Gambacorti-Passerini, MD, Andreas Hochhaus, MD, Jeff H. Lipton, MD PhD, Vamsi Kota, MBBS, Michael W. Deininger, MD PhD, Eric Leip, PhD, Andrea Viqueira, MD, Roxanne Ferdinand, MBBS MFPM, Jorge E. Cortes, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3005.
https://doi.org/10.1182/blood-2018-99-110543
Published: 2018
Journal Articles

The Real World Use of Bosutinib in Patients with Chronic Myeloid Leukaemia

Jane F. Apperley, MD, Jenny L. Byrne, FRCP FRCPath PhD, Graeme Smith, Simone Claudiani, Andrea Viqueira, Roxanne Ferdinand, Angela M Carter, Georgina Nock, Dragana Milojkovic
Journal: Blood
Blood (2016) 128 (22): 5435.
https://doi.org/10.1182/blood.V128.22.5435.5435
Published: 2016
Journal Articles

The Effect of Vascular Occlusive Events on Discontinuation and Cost of Care in Patients Treated with Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Stuart L. Goldberg, MD, Yun Su, MD MPH, MS, Candace Gunnarsson, EdD, MA, William D Irish, PhD, Michael Ryan, MS, Mabel Woloj, MD, Roxanne Ferdinand, MBBS MRCP MFPM, Mark Shapiro, MD
Journal: Blood
Blood (2015) 126 (23): 2797.
https://doi.org/10.1182/blood.V126.23.2797.2797
Published: 2015